Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $70.12 USD
Change Today +0.42 / 0.60%
Volume 2.6M
MYL On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

mylan nv (MYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $76.69
52 Week Low
08/13/14 - $44.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYLAN NV (MYL)

mylan nv (MYL) Details

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. It offers generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. Further, the company manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. was founded in 1961 and is headquartered in Potters Bar, Hertfordshire.

25,000 Employees
Last Reported Date: 03/2/15
Founded in 1961

mylan nv (MYL) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $1.2M
President, Executive Director and Member of S...
Total Annual Compensation: $890.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
President of Mylan North America
Total Annual Compensation: $545.2K
Compensation as of Fiscal Year 2014.

mylan nv (MYL) Key Developments

Pulmatrix, Inc. Enters into ex-US Development Agreement with Mylan N.V

Pulmatrix Inc. announced that it has entered into an ex-US development agreement with Mylan N.V. for the treatment of chronic obstructive pulmonary disease, or COPD. The agreement is for PUR0200, a clinical stage bronchodilator therapy being studied for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from the company's novel iSPERSE inhaled dry powder technology. PUR0200 contains a long-acting muscarinic agent (LAMA) being studied for the treatment of COPD and current clinical development is focused on pharmacokinetic bioequivalence in Europe. Under the terms of the agreement, Pulmatrix will lead the development work and pharmacokinetic clinical study with collaborative support from Mylan.

Mylan N.V. Enter into Additional Credit Extension Amendment

On June 19, 2015, Mylan N.V. entered into an additional credit extension amendment among the company, Mylan Inc. (Borrower), ING Bank N.V., Dublin Branch (Augmenting Lender), certain issuing banks and Bank of America, N.A., as administrative agent (Administrative Agent), to the Revolving Credit Agreement dated as of December 19, 2014, among the company, the Borrower, the lenders and issuing banks party thereto and the Administrative Agent, as amended by Amendment No. 1 to the Revolving Credit Agreement dated as of May 1, 2015. The Amendment provides that the Augmenting Lender will make available $150,000,000 of additional revolving commitments under the Credit Agreement (Increased Commitments), increasing the aggregate principal amount of the revolving commitments available under the Credit Agreement from $1,500,000,000 to $1,650,000,000. No other changes to the terms of the Credit Agreement were effected in connection with the Amendment. Proceeds from the Increased Commitments will be used for working capital, capital expenditures and other lawful corporate purposes.

Mylan Launches Generic Metered-Dose Inhaler for Asthma Therapy in UK

Mylan N.V. launched the bioequivalent alternative to GlaxoSmithKline's Seretide Evohaler, a pressurized metered-dose inhaler for asthma therapy, under the brand name, Sirdupla, in the UK. Sirdupla is a pressurized metered-dose inhaler (pMDI) and is indicated to help treat or prevent symptoms of asthma in adults 18 years of age and older. The product is being manufactured by 3M Drug Delivery Systems.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $70.12 USD +0.42

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,791 JPY +7.50
Becton Dickinson and Co $143.18 USD -0.04
Perrigo Co PLC $183.68 USD -1.38
Shire PLC 5,230 GBp -35.00
Sun Pharmaceutical Industries Ltd 871.00 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 33.0x
Price/Sales 3.7x
Price/Book 3.8x
Price/Cash Flow 39.5x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at